AORI-HAP: a multidimensional risk index to predict in-hospital adverse outcomes in asthma exacerbations
Rattachement africain : cn, au, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Despite therapeutic advancements, asthma exacerbations (AEs) remain a major clinical challenge, with immune-inflammatory patterns incompletely characterized. Current guidelines lack robust multidimensional tools for predicting in-hospital adverse outcomes. Objective To develop and validate the Asthma Outcome Risk Index for Hospitalized Patients (AORI-HAP), integrating multidimensional predictors, and investigate immune-inflammatory mechanisms underlying adverse outcomes. Methods This real-world cohort study enrolled hospitalized AE patients. Univariate analyses identified associations between multidimensional biomarkers and composite outcome (death, ICU admission, invasive ventilation). LASSO logistic regression derived the AORI-HAP, stratifying patients into risk categories. Mediation analysis elucidated mechanistic contributions to adverse outcomes. Results The AORI-HAP identified five independent predictors of adverse outcomes: elevated neutrophil-to-lymphocyte ratio (NLR > 8.3, OR = 9.26, p < 0.001), increased AST/ALT ratio (>1.41, OR = 3.73, p < 0.001), smoking history ≥10 pack-years (OR = 3.54, p = 0.005), D-Dimer levels ≥5 mg/L (OR = 3.25, p = 0.002), and fasting glucose ≥7 mmol/L (OR = 3.20, p = 0.001). Each 3-point increment in the AORI-HAP score corresponded to an additional hospital day ( β = 0.997, 95% CI: 0.78–1.21, p < 0.001), with the model demonstrating strong predictive performance (AUC 0.91, 95% CI 0.86–0.95; sensitivity 90.5%, specificity 69.6%). Mediation analysis revealed that NLR accounted for 26.7% of the total effect linking high-risk status to composite adverse outcome, underscoring its mechanistic relevance. Conclusion AORI-HAP facilitates early risk stratification at admission and personalized management in hospitalized asthma patients. NLR’s mediating role underscores its utility as a predictive biomarker and potential therapeutic target.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- AORI-HAP: a multidimensional risk index to predict in-hospital adverse outcomes in asthma exacerbations
- Date Crossref
- 10/12/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.